Literature DB >> 32125444

The Rate of Hepatic Fibrosis Progression in Patients Post-Fontan.

William N Evans1,2, Ruben J Acherman3,4, Gary A Mayman3,4, Alvaro Galindo3,4, Abraham Rothman3,4, Brody J Winn5, Noel S Yumiaco5, Humberto Restrepo3,4.   

Abstract

This investigation analyzed the rate of hepatic fibrosis progression in post-Fontan patients that underwent hepatic biopsy. The study cohort comprised post-Fontan patients that underwent cardiac catheterization and transvenous liver biopsy between March 2012 and September 2019. We identified 126 patients that met inclusion criteria. Of the 126, 27 (21%) had a lateral tunnel Fontan, and 99 (79%) had an extracardiac Fontan. For the 27 lateral tunnel Fontan patients, age at Fontan was 4 ± 2 years, and for the 99 extracardiac Fontan patients age at Fontan was 4 ± 2 years (p = 0.98). For the 27 lateral tunnel Fontan patients, the average total fibrosis score was 3.0 ± 1.5; and for the 99 extracardiac Fontan patients, the average total fibrosis was 2.7 ± 1.7 (p = 0.48). For the lateral tunnel Fontan patients, the average Fontan duration was 20 ± 6 years; and for the 99 extracardiac Fontan patients, the average Fontan duration was 11 ± 5 years (p < 0.001). For the 27 lateral tunnel Fontan patients, the average rate of fibrosis progression was 0.16 ± 0.10 total fibrosis score/year; and for the 99 extracardiac Fontan patients, the average rate of fibrosis progression was 0.30 ± 0.23 total fibrosis score/year (p < 0.001). In conclusion, our findings suggest that those with extracardiac Fontans have a faster rate of hepatic fibrosis progression than those with lateral tunnel Fontans. More extensive or multi-institutional studies will be needed to confirm these findings and define the clinical significance of discrepant rates of hepatic fibrosis in post-Fontan patients.

Entities:  

Keywords:  Cardiac catheterization; Fontan; Hepatic biopsy; Hepatic fibrosis

Year:  2020        PMID: 32125444     DOI: 10.1007/s00246-020-02331-0

Source DB:  PubMed          Journal:  Pediatr Cardiol        ISSN: 0172-0643            Impact factor:   1.655


  4 in total

1.  Evaluation of Fontan-associated Liver Disease and Ethnic Disparities in Long-term Survivors of the Fontan Procedure: A Population-based Study.

Authors:  Juliet Emamaullee; Sean Martin; Cameron Goldbeck; Brittany Rocque; Arianna Barbetta; Rohit Kohli; Vaughn Starnes
Journal:  Ann Surg       Date:  2022-06-29       Impact factor: 13.787

2.  Extracardiac conduit adequacy along the respiratory cycle in adolescent Fontan patients.

Authors:  Friso M Rijnberg; Séline F S van der Woude; Mark G Hazekamp; Pieter J van den Boogaard; Hildo J Lamb; Covadonga Terol Espinosa de Los Monteros; Lucia J M Kroft; Sasa Kenjeres; Tawab Karim; Monique R M Jongbloed; Jos J M Westenberg; Jolanda J Wentzel; Arno A W Roest
Journal:  Eur J Cardiothorac Surg       Date:  2022-06-15       Impact factor: 4.534

3.  Non-invasive biomarkers of Fontan-associated liver disease.

Authors:  Juliet Emamaullee; Sara Khan; Carly Weaver; Cameron Goldbeck; George Yanni; Rohit Kohli; Yuri Genyk; Shengmei Zhou; Nick Shillingford; Patrick M Sullivan; Cheryl Takao; Jon Detterich; Paul F Kantor; John D Cleveland; Cynthia Herrington; S Ram Kumar; Vaughn Starnes; Sarah Badran; Neil D Patel
Journal:  JHEP Rep       Date:  2021-09-14

4.  4D flow cardiovascular magnetic resonance derived energetics in the Fontan circulation correlate with exercise capacity and CMR-derived liver fibrosis/congestion.

Authors:  Arno A W Roest; Hildo J Lamb; Friso M Rijnberg; Jos J M Westenberg; Hans C van Assen; Joe F Juffermans; Lucia J M Kroft; Pieter J van den Boogaard; Covadonga Terol Espinosa de Los Monteros; Evangeline G Warmerdam; Tim Leiner; Heynric B Grotenhuis; Monique R M Jongbloed; Mark G Hazekamp
Journal:  J Cardiovasc Magn Reson       Date:  2022-03-28       Impact factor: 6.903

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.